Aurinia Pharmaceuticals Wins European Approval of Lupkynis for Lupus
The European Commission has approved Aurinia Pharmaceuticals' (NASDAQ:AUPH) Lupkynis (voclosporin) for lupus nephritis. The approval triggers a $30M milestone payment from partner Otsuka Pharmaceutica
Otsuka's Oral Drug Combo for Leukemia Gets Review in EU
The European Medicines Agency (EMA) accepted Astex Pharmaceuticals' application seeking approval for the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) as an initial treatment of
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Akebia Therapeutics Inc (NASDAQ:AKBA) announced initial findings from an investigator-sponsored study evaluating vadadustat for Acute Respiratory Distress Syndrome (ARDS) with COVID-19 and hypoxemia.
Otsuka's high blood pressure treating system Paradise meets main goal in trial
Otsuka (OTCPK:OTSKF) (OTCPK:OTSKY) said its Paradise Ultrasound Renal Denervation (uRDN) system met the main goal of trial evaluating the device to treat patients with uncontrolled hypertension ( high
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants The FDA's independe
Nikkei 225 Up 1.4% on Wall Street Cues and Inflation Outlooks
05:51 AM EDT, 06/27/2022 (MT Newswires) -- The Nikkei 225 opened higher Monday on Wall Street cues and rose to the close, finishing up 1.4% after the most-recent University of Michigan consumer survey
Centessa stock falls as company pulls plug on lixivaptan kidney disease program after liver issue in patient
Centessa Pharmaceuticals (NASDAQ:CNTA) stock fell ~11% premarket June 2, after the said it will discontinue developing lixivaptan for a type of kidney disease. The company will discontinue development
Why Are Akebia Therapeutics Shares Falling Today?
Akebia Therapeutics Inc (NASDAQ:AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat.Otsuka sent a written notice to Akebia on
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
The FDA has issued a complete response letter (CRL) to Akebia Therapeutics Inc's (NASDAQ:AKBA) marketing application (NDA) for vadadustat for anemia due to chronic kidney disease (CKD). Vadadustat is
Reuters Events to hold a webinar
Patient Services: Connected & Simplified Webinar to be held on March 10 at 11 am.